Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 17/20 | 0.81 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.81 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.81 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877915 | 0.90 | FGFR1 (0.81) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL18162423 | 0.90 | FGFR1 (0.83) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30274661 | 0.89 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL29412748 | 0.89 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL16659467 | 0.89 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30070526 | 0.89 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30070306 | 0.89 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL18153614 | 0.89 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL18153616 | 0.89 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL20025867 | 0.87 | FGFR1 (0.80) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737377-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Eisai R&D Management Co., Ltd. (JP) | 2020-11-18 | — | — | EP | claimed |
| WO-2021231928-A1 | A METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN FGFR4 INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-18 | — | — | WO | disclosed |
| EP-3503923-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Eisai R&D Management Co., Ltd. (JP) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039324-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-01 | — | — | WO | disclosed |